On average, those using semaglutide for diabetes experience noticeable weight loss, enhanced energy levels, and better overall well-being
Semaglutide begins working as soon as you start taking it, and produces weight loss in a matter of weeks, according to studies of people with obesity
10 Adverse events 5% in SUSTAIN 5 8,10 AEs occurring in 5% of participants treated with Ozempic in SUSTAIN 5 Incidence of severe hypoglycemia was 1.5% across all placebo-controlled trials 1 Incidence of severe hypoglycemia or blood glucose-confirmed hypoglycemia (% of patients) was 8,10 : 8.3% with Ozempic 0.5 mg + basal insulin MET 10.7% with Ozempic 1 mg + basal insulin MET 5.3% with placebo + basal insulin MET Patients receiving Ozempic in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia 1 ADA=American Diabetes Association

Reported Issues: Consumers report: That the supplement did not lead to weight loss or appetite suppression as advertised That the product was marketed using misleading claims about GLP-1 support That they paid for a product that did not provide the promised benefits That the supplements are promoted as alternatives to GLP-1 medications, despite not functioning like prescription GLP-1 drugs That marketing materials imply that these supplements are scientifically and medically proven and reliable, when evidence may be lacking That they would not have purchased the supplements if they had known the claims were not supported by reliable scientific evidence Experiencing adverse side effects such as stomach pain, nausea, or weight gain Why Individuals Should Be Concerned: Potential claims include: Economic loss Safety risk False advertising Product defect Performance vs
doi: 10.3168/jds.2015-10157 93 OsorioJ
Doing so exceeds the traditional scope of pharmacy compounding and violates federal law